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ABSTRACT
The Working Group on Severe Asthma of the Korean Academy of Allergy and Clinical 
Immunology recently published an expert opinion paper on the management of severe 
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asthma in Korea. When developing a consensus, the working group encountered several 
diagnostic and treatment issues and decided to perform a questionnaire survey of Korean 
specialists with regard to severe asthma. An e-mail with a uniform resource locator link to 
the questionnaire was sent to 121 asthma specialists, of whom 44.6% responded. The most 
commonly accepted definitions of severe asthma were a history of fatal exacerbation or an 
asthma-triggered need for mechanical ventilation, 3–4 oral corticosteroid (OCS) bursts/
year, and maintenance of OCS therapy for 3–6 months per year. Before diagnosing severe 
asthma, most physicians contemplate chest computed tomography, seek to control chronic 
rhinosinusitis, and consider poor inhaler compliance. For patients with uncontrolled severe 
asthma accompanied by type 2 (T2)-high inflammation, most biologics available in Korea 
were considered appropriate, but gaps were apparent in terms of T2-low asthma treatments. 
These findings about specialist perception of diagnosis and treatment of severe asthma will 
inform the use of emerging new drugs and facilitate personalized therapy.
Keywords: Asthma; diagnosis; therapeutics; disease management; surveys and questionnaires; 
biological products; standards; consensus
INTRODUCTION
More than 50% of the total medical costs of asthma are attributed to severe asthma, which 
affects only 3%–5% of all asthmatics.1-4 The Global Initiative for Asthma and the European 
Respiratory Society/American Thoracic Society have proposed definitions of severe asthma.5,6 
A key shared feature is uncontrolled asthma even after the highest level of treatment-high-
dose inhaled corticosteroid (ICS)/long-acting beta-2 agonist (LABA) combined with second 
controllers. However, it is well known that a gap exists between the guidelines and real 
clinical practice especially in terms of diagnosis and treatment.4,7-10 The Korean Academy of 
Allergy and Clinical Immunology (KAAACI) organized a Working Group on Severe Asthma 
and recently published an expert opinion paper on the management of severe asthma in 
Korea.11 When developing the consensus, the working group encountered several diagnostic 
and treatment issues.
A concept of severe asthma was once investigated in the previous survey by asking a key 
feature of severe asthma, such as asthma aggravation by stepping down treatment, frequent 
exacerbation, uncontrolled asthma despite higher treatment steps, and serious exacerbation.10 
In that survey, asthma aggravation by stepping down treatment was the most common feature 
of severe asthma. Nevertheless, we still meet several questions during our daily clinical 
practice. For example, how should the examinations prior to a differential diagnosis be 
scheduled? Is it appropriate to consider risk factors or comorbidities? What level of OCS use, 
or number of oral corticosteroid (OCS) bursts, define severe asthma? Clinician preferences 
also differ widely in terms of biologics for patients with severe asthma (sometimes used off-
label). No uniform treatment flow has appeared. It is also not clear whether inflammatory 
biomarkers can be used to select biologics. To clarify these issues, the working group 
performed a questionnaire survey exploring the diagnostic and treatment choices of Korean 
specialists in cases of severe asthma. This brief report summarizes the results.
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MATERIALS AND METHODS
We performed a questionnaire survey of specialists in adult asthma recruited from 2 
representative societies: the Working Group on Severe Asthma of the KAAACI and the steering 
committee of the Asthma and Chronic Obstructive Respiratory Disease (COPD) study group 
of the Korean Academy of Tuberculosis and Respiratory Diseases. Additional participants 
were recruited during participation in the “Severe Asthma Symposium” held on September 21, 
2019, where an “Expert opinion paper about the diagnosis and treatment of severe asthma” was 
discussed in depth. An e-mail was sent to 121 specialists; it explained why the questionnaire was 
being circulated (the need to learn more about the diagnosis and treatment of severe asthma) 
and provided a uniform resource locator link to the questionnaire. In total, 54 specialists 
completed the questionnaire (response rate 44.6%). Respondents also provided demographic 
data (age, sex, and area of practice [allergy or pulmonology]).
The questionnaire was developed on the basis of the results of semi-structured interviews 
with the members of the Working Group of Severe Asthma of the KAAACI who participated 
in the preparation of an expert opinion paper entitled “Evaluation and management of 
difficult-to-treat and severe asthma.” A draft questionnaire (5 questions) was prepared in 
May 2019 after brainstorming the most ambiguous issues. A pilot survey was completed 
by 29 physicians from May 25 to June 1, 2019, and the results and additional feedback were 
reviewed by the working group. The results revealed that more detailed questions were 
required to improve clarity, especially in areas in which knowledge seemed to be lacking 
and to explore issues to which the physicians did not respond. Participants also suggested 
21 additional questions, of which 15 were chosen by the working group. The revised 
questionnaire included 4 parts (as the expert opinion paper did), and explored asthma 
definitions (3 items), diagnosis (3 items), treatment (8 items), and asthma-COPD overlap 
(ACO, 1 item). Questions explored how clinicians defined severe asthma, the roles played 
by comorbidities and modifiable risk factors, and treatment options including add-on 
therapies. The answers were of 2 types: 1) ticking a box indicating the extent of agreement 
with a statement (from 1 [disagree] to 5 [strongly agree]); and 2) selecting from a multiple-
choice list. Agreement scores were assessed based on means ± standard deviations of scores 
awarded and the numbers (with percentages) of answers to multiple-choice questions.
RESULTS
In total, 54 physicians answered the questionnaire. The age distribution was: 30–39 years 
(42.6%); 40–49 years (35.2%); over 50 years (20.4%); and no age given (1.9%). Of the 
respondents, 51.9% were males, 55.6% had an allergy subspecialty, and 44.4% had a 
pulmonology subspecialty.
Definition of severe asthma
As shown in Table 1, the most agreed-upon criterion was a history of fatal exacerbation or 
an asthma-triggered need for mechanical ventilation in addition to uncontrolled asthma 
symptoms and decreased lung function (Supplementary Fig. S1). Most specialists considered 
that 3–4 OCS bursts/year was an appropriate criterion. Additionally, most physicians agreed 
that asthma patients who required OCS for 3–6 months/year had severe asthma.
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Diagnosis of severe asthma
As shown in Table 2 and Supplementary Fig. S2, most physicians agreed that chest computed 
tomography (CT) and chronic rhinosinusitis (CRS) control should be considered prior to 
diagnosis of severe asthma. The most agreed-upon risk factor that should be modified before 
diagnosis was poor compliance with or cessation of inhaler use.
Treatment of severe asthma
As shown in Table 3, the most agreed-upon indications for biologic commencement were a 
combination of high-dose ICS-LABA with tiotropium or a need for OCS maintenance. However, 
most physicians did not start biologics when asthma was well-controlled with high-dose ICS-
510https://e-aair.org https://doi.org/10.4168/aair.2021.13.3.507
Specialist Perception of Severe Asthma
Table 2. Considerations prior to diagnosis of severe asthma
Questions Value
Q4. Do you agree that the tests listed below are appropriate during differential diagnosis of severe asthma?
Chest CT 4.32 ± 1.07
Anti-Aspergillus IgE level 3.18 ± 0.96
Serum ANCA 3.06 ± 1.17
Laryngoscopy 2.98 ± 1.26
Bronchoscopy 2.43 ± 1.06
Q5. Do you agree that the risk factors listed below should be modified prior to diagnosis of severe asthma?
Chronic rhinosinusitis 4.31 ± 0.87
Obesity 3.91 ± 1.01
Depression/anxiety disorder 3.74 ± 0.89
Gastro-esophageal reflux disease 3.64 ± 1.02
Obstructive sleep apnea 3.47 ± 0.99
Q6. Do you agree that the risk factors listed below should be modified prior to diagnosis of severe asthma?
Poor inhaler compliance 4.82 ± 0.51
Lack of inhaler skill 4.64 ± 0.68
Stoppage of asthma medication because of side-effects 4.61 ± 0.68
Smoking 4.31 ± 0.93
Exposure to sensitized allergens or nonspecific stimuli that worsen the respiratory symptoms 4.08 ± 0.96
Each score is a mean ± standard deviation determined by considering all answers from 1 (disagree) to 5 (strongly agree). The answers are given in decreasing order.
CT, computed tomography; IgE, immunoglobulin E; ANCA, anti-neutrophil cytoplasmic antibodies.
Table 1. Defining severe asthma
Questions Value
Q1. Do you agree that the criteria listed below appropriately define severe asthma?
A fatal exacerbation or at least one episode of mechanical ventilation required because of asthma during the last year 4.69 ± 0.58
At least 2 hospitalizations or ER visits/year 4.31 ± 0.82
Uncontrolled asthma symptoms (at least 3 of daytime symptoms, night awakening, activity limitations, and/or reliever use) 4.30 ± 0.72
At least 2 OCS bursts/year 4.06 ± 0.76
Decreased lung function (FEV1 < 80%) 3.56 ± 0.90




Not a useful criterion 4 (7.5)
More than 7 0 (0)
Q3. What duration of OCS maintenance/year appropriately defines severe asthma?
6 mon 21 (38.9)
3 mon 16 (29.7)
Not a useful criterion 11 (20.4)
9 mon 4 (7.4)
12 mon 1 (1.9)
No answer 1 (1.9)
Each score is a mean ± standard deviation determined by considering all answers from 1 (disagree) to 5 (strongly agree); †Each multiple-choice question was 
scored as a number (%).The answers are given in decreasing order.
ER, emergency room; OCS, oral corticosteroid; FEV1, forced expiratory volume in 1 second.
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Table 3. Treatment of severe asthma
Questions Value
Q7.  Do you agree that the prior treatments listed below would be appropriate when considering whether to start biologics in patients 
with severe asthma?
High dose ICS-LABA + tiotropium 4.42 ± 0.83
Maintenance of OCS 4.35 ± 1.07
High dose ICS-LABA + tiotropium + LTRA 4.30 + 0.84
High dose ICS-LABA 4.17 ± 0.80
Medium dose ICS-LABA + tiotropium + LTRA 3.79 + 1.15
Q8.  What duration of prior high-dose ICS-LABA treatment is appropriate when considering whether to start biologics in patients with 
severe asthma?
I do not consider biologics if the asthma is well controlled by high-dose ICS-LABA 22 (40.7)
6 mon 12 (22.3)
More than 12 mon 8 (14.9)
3 mon 7 (13.0)
9 mon 5 (9.3)
Q9. How much prior OCS maintenance is appropriate when considering whether to start biologics in patients with severe asthma?
6 mon 21 (38.9)
3 mon 16 (29.7)
I prefer biologics to OCS maintenance if the biologics are available and affordable 10 (18.5)
9 mon 5 (9.3)
More than 12 mon 2 (3.8)
I do not consider biologics if the asthma is well controlled by OCS 0 (0)
Q10.  Do you agree that it would be appropriate to consider stopping biologics in patients with severe asthma under the following 
conditions?
No asthma exacerbation for 1 yr 3.98 + 0.77
I do not consider stopping biologics if they are available and affordable 3.50 + 0.96
A target amount has been delivered 3.35 + 1.23
Improved lung function (FEV1) 3.33 + 1.03
A decreased blood eosinophil or FeNO level 3.08 + 1.05
Q11. How much improvement in lung function (FEV1) is appropriate before considering whether to stop biologics in severe asthma patients?




≥ 50% 3 (5.6)
No answer 6 (11.1)
Q12 & Q13.  Do you agree that the add-on treatments listed below are appropriate for patients with uncontrolled T2-high or T2-low severe 
asthma in addition to high-dose ICS-LABA with tiotropium?
T2-high
Reslizumab 4.67 ± 0.48
Benralizumab 4.59 ± 0.53
Mepolizumab 4.59 ± 0.53
Dupilumab 4.51 ± 0.67
Omalizumab 3.72 ± 0.95
T2-low
Macrolide 3.75 ± 0.92
Tezepelumab 3.63 ± 1.09
Roflumilast 3.44 ± 1.00
Bronchial thermoplasty 2.59 ± 1.00
Imatinib 2.52 ± 0.91
Q14.  Do you agree that the biomarkers mentioned below are of assistance when considering anti-IL5/5R therapy for patients with severe 
asthma?
Blood eosinophil count 4.74 ± 0.45
FeNO level 4.17 ± 0.86
Atopic status 3.40 ± 1.17
Total IgE level 3.17 ± 1.11
Periostin level 3.15 ± 1.05
Each score is a mean ± standard deviation determined by considering all answers from 1 (disagree) to 5 (strongly agree); Each multiple-choice question was 
scored as a number (%). The answers are given in decreasing order.
ICS, inhaled corticosteroid; LABA, long-acting beta-2 agonist; OCS, oral corticosteroid; LTRA, leukotriene receptor antagonist; FEV1, forced expiratory volume in 1 
second; FeNO, fractional exhaled nitric oxide; T2, type 2; IL5, interleukin 5; IL5R, interleukin 5 receptor; IgE, immunoglobulin E.
LABA without other add-on treatments such as tiotropium or a leukotriene receptor antagonist. 
They considered commencing biologics when asthmatic patients required OCS for 3–6 months/
year and stopped biologics when no asthma exacerbation was noted for 1 year. Notably, no 
clinician answered “yes” to: “I do not consider biologics if asthma is well-controlled via the 
maintenance of OCS.” Thus, all agreed that OCS maintenance should be avoided if at all possible.
Most physicians did not consider stopping biologics according to lung function 
improvement. For patients with uncontrolled severe asthma and high-type 2 (T2) airway 
inflammation, all biologics available in Korea were considered appropriate, but add-on 
treatments for T2-low asthma were considered variously, with a wide gap. The blood 
eosinophil level was the most agreed-upon biomarker for the choice of anti-interleukin 5 
(IL5)/interleukin 5 receptor (5R) therapy.
ACO in severe asthma
Respondents were asked about which criteria are appropriate when defining ACO in patients 
with severe asthma. As shown in Fig. 1, the most agreed-upon criteria were a smoking history 
of more than 10 packs-year (96.3%) and a post-bronchodilator forced expiratory volume in 1 
second (FEV1)/forced vital capacity (FVC) ratio < 0.7 (94.4%).
DISCUSSION
Fig. 2 presents the results of our questionnaire survey of specialist perception of severe asthma 
in Korea. First, we identified the need to use a lung function test when seeking to define 
severe asthma; most physicians agreed because the test is widely available in primary clinics 
and the National Health Insurance Service emphasizes the importance of lung function tests 
when assessing the quality of asthma management.12 Secondly, we found that chest CT, CRS 
improvement, and inhaler adherence were usually scheduled/checked prior to the diagnosis of 
severe asthma. Thirdly, we clarified opinions about add-on treatments, including when to start 
or stop biologics, useful biomarkers, and medications. Generally, physicians consider add-on 
biologics when OCS maintenance is required for more than 3–6 months/year or when high-dose 
ICS-LABA with tiotropium is consistently needed for asthma control. The blood eosinophil 
level was the most agreed-upon biomarker in terms of when to start IL5/5R therapy. For patients 
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Anthracofibrosis in chest CT or bronchoscopy
Negative bronchodilator response
Age ≥ 65 years
Emphysema in chest CT
Post bronchodilator FEV1/FVC < 0.7
Smoking history ≥ 10 pack-year
Fig. 1. Proportions of agreement (mean scores of over 3) in terms of defining ACO in patients with severe asthma. 
ACO, asthma-Chronic Obstructive Respiratory Disease overlap; FEV1, forced expiratory volume in 1 second; FVC, 
forced vital capacity; CT, computed tomography.
with T2-high, severe uncontrolled asthma, most biologics available in Korea were considered 
useful, but differences were evident in terms of add-on treatment choices for patients with T2-
low severe asthma. Drugs that are effective in such patients require further research. Physicians 
consider ACO status when patients with severe asthma have smoking histories of more than 10 
packs-year or fixed airflow limitations (post-bronchodilator FEV1/FVC ratio < 0.7).
Most guidelines suggest that severe asthma be diagnosed after chronological observation of the 
patient and the success (or not) of asthma control, and the exacerbation risk. Many physicians 
find this confusing; a gap is evident between the guidelines and real clinical practice.6-9 Our 
survey results reflect expert opinions about the chronological definition of severe asthma 
formed by personal clinical experience. We explored issues such as what duration of OCS 
maintenance is required before starting biologics, what examinations should be scheduled, and 
what comorbidities and risk factors should be considered prior to a diagnosis of severe asthma. 
Our results are informative, but may be appropriate only in Korea; medical circumstances 
differ worldwide. Also, the response rate to questionnaire survey was under 50%, which could 
be increased if diverse forms of survey would be applied. In conclusion, the findings of our 
survey on specialist perception of severe asthma diagnosis and treatment will inform the use of 
emerging new drugs and help facilitate personalized therapy.
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Consider before diagnosis
Check
    Chest CT
    Anti-aspergillus IgE
    ANCA
Control 
    CRS, obesity, depression/anxiety
Modify 
    Poor compliance to inhaler
    Inappropriate inhaler skill
    Side effect of treatment
Add-on treatment
Type 2 high
    Anti-IL5/5R
    Anti-IL4R
    Anti-IgE
Type 2 low
    Macrolide
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    Anti-TSLP Specialists'
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When to start biologics
Maintenance of OCS (≥ 3–6 months)
High dose ICS/LABA + tiotropium
When to stop biologics
No asthma exacerbation during 1 year







Hospitalization or ER visit ≥ 1 time/year
OCS burst ≥ 2 times/year
Fatal exacerbation ≥ 1 time/year
Decreased lung function (FEV1 < 80%)
Fig. 2. A graphical summary of specialists' perceptions of severe asthma. 
ER, emergency room; OCS, oral corticosteroid; FEV1, forced expiratory volume in 1 second; CT, computed tomography; IgE, immunoglobulin E; ANCA, anti-
neutrophil cytoplasmic antibodies; CRS, chronic rhinosinusitis; ICS, inhaled corticosteroid; LABA, long-acting beta-2 agonist; IL5, interleukin 5; IL5R, interleukin 
5 receptor; IL4R, interleukin 4 receptor; PDE4, phosphodiesterase 4; TSLP, thymic stromal lymphopoietin.
SUPPLEMENTARY MATERIALS
Supplementary Fig. S1
The extents of agreement (mean scores of over 3) in terms of defining severe asthma.
Click here to view
Supplementary Fig. S2
The extents of agreement (mean scores of over 3) in terms of items considered before 
diagnosing severe asthma.
Click here to view
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